Base de datos : MEDLINE
Búsqueda : adenocarcinoma [Palabras]
Referencias encontradas : 231031 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 23104 va a la página                         

  1 / 231031 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29099399
[Au] Autor:van Hilst J; de Rooij T; Klompmaker S; Rawashdeh M; Aleotti F; Al-Sarireh B; Alseidi A; Ateeb Z; Balzano G; Berrevoet F; Björnsson B; Boggi U; Busch OR; Butturini G; Casadei R; Del Chiaro M; Chikhladze S; Cipriani F; van Dam R; Damoli I; van Dieren S; Dokmak S; Edwin B; van Eijck C; Fabre JM; Falconi M; Farges O; Fernández-Cruz L; Forgione A; Frigerio I; Fuks D; Gavazzi F; Gayet B; Giardino A; Bas Groot K; Hackert T; Hassenpflug M; Kabir I; Keck T; Khatkov I; Kusar M; Lombardo C; Marchegiani G; Marshall R; Menon KV; Montorsi M; Orville M; de Pastena M; Pietrabissa A; Poves I; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS)
[Ad] Dirección:*Department of Surgery, Cancer Center Amsterdam, Academic Medical Center, Amsterdam, the Netherlands †Department of Surgery, Southampton University Hospital NHS Foundation Trust, Southampton, United Kingdom ‡Department of Surgery, San Raffaele Hospital, Milan, Italy §Department of Surgery, Morriston Hospital, Swansea, United Kingdom ¶Department of Surgery, Virginia Mason Medical Center, Seattle, United States ||Department of Surgery, Karolinska Institute, Stockholm, Sweden **Department of General and HPB surgery and liver transplantation, Ghent University Hospital, Ghent, Belgium ††Department of Surgery, Linköping University, Linköping, Sweden ‡‡Department of Surgery, Universitá di Pisa, Pisa, Italy §§Department of Surgery, Pederzoli Hospital, Peschiera, Italy ¶¶Department of Surgery, S. Orsola-Malpighi Hospital, Bologna, Italy ||||Department of Surgery, Universitätsklinikum Freiburg, Freiburg, Germany ***Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands †††Department of Surgery, Pancreas Institute, Verona University Hospital, Verona, Italy ‡‡‡Department of Surgery, Hospital of Beaujon, Clichy, France §§§Department of Surgery, Oslo University Hospital and Institute for Clinical Medicine, Oslo, Norway ¶¶¶Department of Surgery, Erasmus MC, Rotterdam, the Netherlands ||||||Department of Surgery, Hopital Saint Eloi, Montpellier, France ****Department of Surgery, Hospital Clínic de Barcelona, Barcelona, Spain ††††Department of Surgery, Niguarda Ca' Granda Hospital, Milan, Italy ‡‡‡‡Department of Surgery, Institut Mutualiste Montsouris, Paris, France §§§§Department of Surgery, Humanitas University Hospital, Milan, Italy ¶¶¶¶Department of Surgery, Heidelberg University Hospital, Heidelberg, Germany ||||||||Department of Surgery, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom *****Clinic for Surgery, UKSH Campus Lübeck, Lübeck, Germany †††††Department of Surgery, Moscow Clinical Scientific Center, Moscow, Russian Federation ‡‡‡‡‡Department of Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia §§§§§Department of Surgery, King's College Hospital NHS Foundation Trust, London, United Kingdom ¶¶¶¶¶Department of Surgery, University hospital Pavia, Pavia, Italy ||||||||||Department of Surgery, Hospital del Mar, Barcelona, Spain ******Department of Surgery, University Hospital Birmingham, Birmingham, United Kingdom ††††††Surgical Clinic, Department of clinical and experimental sciences, University of Brescia, Brescia, Italy ‡‡‡‡‡‡Department of Surgery, The Freeman Hospital Newcastle Upon Tyne, Newcastle, United Kingdom.
[Ti] Título:Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study.
[So] Fuente:Ann Surg;, 2017 Nov 02.
[Is] ISSN:1528-1140
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:OBJECTIVE: The aim of this study was to compare oncological outcomes after minimally invasive distal pancreatectomy (MIDP) with open distal pancreatectomy (ODP) in patients with pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: Cohort studies have suggested superior short-term outcomes of MIDP vs. ODP. Recent international surveys, however, revealed that surgeons have concerns about the oncological outcomes of MIDP for PDAC. METHODS: This is a pan-European propensity score matched study including patients who underwent MIDP (laparoscopic or robot-assisted) or ODP for PDAC between January 1, 2007 and July 1, 2015. MIDP patients were matched to ODP patients in a 1:1 ratio. Main outcomes were radical (R0) resection, lymph node retrieval, and survival. RESULTS: In total, 1212 patients were included from 34 centers in 11 countries. Of 356 (29%) MIDP patients, 340 could be matched. After matching, the MIDP conversion rate was 19% (n = 62). Median blood loss [200 mL (60-400) vs 300 mL (150-500), P = 0.001] and hospital stay [8 (6-12) vs 9 (7-14) days, P < 0.001] were lower after MIDP. Clavien-Dindo grade ≥3 complications (18% vs 21%, P = 0.431) and 90-day mortality (2% vs 3%, P > 0.99) were comparable for MIDP and ODP, respectively. R0 resection rate was higher (67% vs 58%, P = 0.019), whereas Gerota's fascia resection (31% vs 60%, P < 0.001) and lymph node retrieval [14 (8-22) vs 22 (14-31), P < 0.001] were lower after MIDP. Median overall survival was 28 [95% confidence interval (CI), 22-34] versus 31 (95% CI, 26-36) months (P = 0.929). CONCLUSIONS: Comparable survival was seen after MIDP and ODP for PDAC, but the opposing differences in R0 resection rate, resection of Gerota's fascia, and lymph node retrieval strengthen the need for a randomized trial to confirm the oncological safety of MIDP.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:Publisher
[do] DOI:10.1097/SLA.0000000000002561


  2 / 231031 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29098805
[Au] Autor:Kumagai R; Muramatsu A; Nakajima R; Fujii M; Kaino K; Katakura Y; Okumura N; Ohara G; Kagohashi K; Satoh H; Yagyu H
[Ad] Dirección:Department of Endocrinology and Metabolism, Tsukuba University Hospital Mito Clinical Education and Training Center, Mito Kyodo General Hospital, Mito, Ibaraki, Japan.
[Ti] Título:Acute-onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma.
[So] Fuente:J Diabetes Investig;8(6):798-799, 2017 Nov.
[Is] ISSN:2040-1124
[Cp] País de publicación:Japan
[La] Idioma:eng
[Ab] Resumen:A case of acute-onset type 1 diabetes mellitus concomitant with pneumonitis and vitiligo is described.
[Pt] Tipo de publicación:LETTER
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:In-Process
[do] DOI:10.1111/jdi.12627


  3 / 231031 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29098619
[Au] Autor:Elena C; Giorgio M; Annik L; Giacomo F; Mariangela P
[Ad] Dirección:Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100, Latina, Italy. elena.cavarretta@uniroma1.it.
[Ti] Título:The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
[So] Fuente:Adv Exp Med Biol;1000:103-129, 2017.
[Is] ISSN:0065-2598
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin, are powerful chemotherapeutic drugs used both in children and adult populations. Their properties made them particularly suitable for a large variety of neoplasms including breast adenocarcinoma, small cell lung cancer and acute leukemia. Early and late anthracycline-induced cardiotoxicity is a well-known phenomenon, and the incidence of heart failure in patients receiving doxorubicin is 2.2%, with a mortality rate over 60% at 2 years. Prognosis can be improved by prevention, early detection and treatment. A specific treatment for anthracycline-induced cardiotoxicity is not yet available, but non-pharmacological measures such as exercise, lifestyle changes and control of risk factors have shown a cardioprotective effect. Exercise training represents a viable non-pharmacological treatment as it increases cardiovascular reserve and endothelial function, regulates proapoptotic signaling, protects against reactive oxygen species (ROS), and decreases autophagy/lysosomal signaling. However, no current guidelines are available for prevention management in cancer patients. Pharmacological measures both for prevention and treatment are those used for heart failure (ß-blockers, angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, statins, dexrazoxane and aldosteron antagonists). In this chapter, we will discuss how the evaluation, monitoring and prevention of chemotherapy-related cardiomyopathy is correlated with physical exercise.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:In-Data-Review
[do] DOI:10.1007/978-981-10-4304-8_8


  4 / 231031 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29098434
[Au] Autor:Milano RV; Viale E; Bartel MJ; Notaristefano C; Testoni PA
[Ad] Dirección:Division of Gastroenterology and Gastrointestinal Endoscopy, Vita Salute San Raffaele University, Scientific Institute San Raffaele, Via Olgettina 60, 20132, Milan, Italy. rezavmilano@gmail.com.
[Ti] Título:Resection outcomes and recurrence rates of endoscopic submucosal dissection (ESD) and hybrid ESD for colorectal tumors in a single Italian center.
[So] Fuente:Surg Endosc;, 2017 Nov 02.
[Is] ISSN:1432-2218
[Cp] País de publicación:Germany
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Endoscopic submucosal dissection (ESD) and hybrid-ESD techniques are treatment modalities for colorectal neoplasia, although mostly used in the Eastern hemisphere. Only few data on ESD for colorectal neoplasia have been published in the West. We report the outcomes of colorectal ESD and hybrid ESD in a single Italian center. METHODS: We retrospectively evaluated the outcomes of all ESD and hybrid-ESD procedures for colorectal neoplasia performed over the first 2-year experience from a prospectively recorded database. Neuroendocrine tumors and adenocarcinoma with submucosal infiltration through the submucosal (SM) 2 layer or deeper were excluded. The primary outcome was the recurrence rate at the 6- to 12-month follow-up. RESULTS: Fifty-two patients were included in the study, of which 23 underwent ESD and 29 hybrid ESD. The mean lesion sizes for ESD and hybrid ESD were similar (25.8 vs. 25.4 mm, p = 0.940), while median procedure length was significantly longer for ESD (120 vs. 60 min, p < 0.001). ESD and hybrid ESD yielded similar en-bloc resection rate (82.6 vs. 82.8%) and R0 resection rate (34.8 vs. 31%). ESD had a lower neoplasia recurrence rate than hybrid ESD (11.7 vs. 20%) and a lower bleeding rate (0 vs. 8.7%). One perforation occurred in the hybrid-ESD cohort and two perforations in the ESD cohort, of which one required surgical intervention. Non-recurrence at follow-up was associated with R0 status, en-bloc resection, and lesion size ≤ 20 mm. CONCLUSION: Our outcomes are comparable with other studies in Western series. Studies addressing the cost effectiveness of ESD and comparing its long-term outcome with endoscopic mucosal resection in the West are needed.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:Publisher
[do] DOI:10.1007/s00464-017-5928-8


  5 / 231031 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29098307
[Au] Autor:Schmidt T; Mönig SP
[Ad] Dirección:Klinik für Allgemein­, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69117, Heidelberg, Deutschland. thomas.schmidt1@med.uni-heidelberg.de.
[Ti] Título:[Therapeutic approach in oligometastatic gastric and esophageal cancer].
[Ti] Título:Therapeutisches Vorgehen beim oligometastasierten Magen- und Ösophaguskarzinom..
[So] Fuente:Chirurg;, 2017 Nov 02.
[Is] ISSN:1433-0385
[Cp] País de publicación:Germany
[La] Idioma:ger
[Ab] Resumen:The therapeutic approach to patients with oligometastatic gastric cancer and esophageal cancer is currently undergoing a shift towards a more aggressive therapy including surgical resection. In the current German S3 guidelines surgical treatment of metastatic disease is not recommended; however, nowadays interdisciplinary tumor boards have to evaluate such patients increasingly more often. On an individual basis a radical surgical resection of the primary tumor and the metastases is considered and performed in patients who respond well to multimodal chemotherapy concepts. In this review article the currently available data from the literature are discussed and a foundation for individually extended surgical approaches is presented. Together with the currently available results of the FLOT 3 study and the mostly retrospective studies, it seems to be possible to identify patients who would profit from such an aggressive treatment. In the future randomized prospective studies, such as the RENAISSANCE/FLOT 5 study and the GASTRIPEC study will have to evaluate whether an aggressive surgical therapy within multimodal therapy concepts of metastatic gastric and esophageal carcinomas is warranted.
[Pt] Tipo de publicación:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:Publisher
[do] DOI:10.1007/s00104-017-0548-3


  6 / 231031 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29098306
[Au] Autor:Schröder W; Lambertz R; van Hillegesberger R; Bruns C
[Ad] Dirección:Klinik und Poliklinik für Allgemein­, Viszeral- und Tumorchirurgie, Universitätsklinik Köln, Kerpener Str. 62, 90933, Köln, Deutschland. wolfgang.schroeder@uni-koeln.de.
[Ti] Título:[Differentiated surgical approach for adenocarcinoma of the gastroesophageal junction].
[Ti] Título:Differenziertes chirurgisches Vorgehen bei Adenokarzinomen des ösophagogastralen Übergangs..
[So] Fuente:Chirurg;, 2017 Nov 02.
[Is] ISSN:1433-0385
[Cp] País de publicación:Germany
[La] Idioma:ger
[Ab] Resumen:For adenocarcinoma of the gastroesophageal junction (GEJ) the classification of Siewert with its three subtypes is well established as a practical approach to surgical treatment. Transthoracic esophagectomy with gastric tube formation is generally accepted as the surgical standard for adenocarcinoma of the distal esophagus (GEJ type I). Intrathoracic esophagogastrostomy has become the most frequently used anastomotic technique (Ivor Lewis esophagectomy). Both the abdominal and thoracic part can be safely performed with a minimally invasive access. For subcardiac gastric cancer (GEJ type III) transhiatal extended gastrectomy is the resection of choice. For true cardiac carcinomas (GEJ type II) it has not yet been decided which of the abovementioned surgical procedures offers the best long-term survival. If technically possible in terms of a complete resection, transhiatal extended gastrectomy should be preferred because of a better postoperative quality of life. For GEJ type II tumors a minimally invasive approach is not recommended if the extent of resection cannot be safely determined preoperatively.
[Pt] Tipo de publicación:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:Publisher
[do] DOI:10.1007/s00104-017-0544-7


  7 / 231031 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29098284
[Au] Autor:Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
[Ad] Dirección:Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
[Ti] Título:Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
[So] Fuente:JAMA Oncol;, 2017 Nov 02.
[Is] ISSN:2374-2445
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Importance: Although patients with resected pancreatic adenocarcinoma are at high risk for disease recurrence, few biomarkers are available to inform patient outcomes. Objective: To evaluate the alterations of the 4 main driver genes in pancreatic adenocarcinoma and patient outcomes after cancer resection. Design, Setting, and Participants: This study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013). Associations of driver gene alterations with disease-free survival (DFS) and overall survival (OS) were evaluated using Cox proportional hazards regression with estimation of hazard ratios (HRs) and 95% CIs and adjustment for age, sex, tumor characteristics, institution, and perioperative treatment. Data were collected September 9, 2012, to June 28, 2016, and analyzed December 17, 2016, to March 14, 2017. Main Outcomes and Measures: The DFS and OS among patients with resected pancreatic adenocarcinoma. Results: Of the 356 patients studied, 191 (53.7%) were men and 165 (46.3%) were women, with a median (interquartile range [IQR]) age of 67 (59.0-73.5) years. Patients with KRAS mutant tumors had worse DFS (median [IQR], 12.3 [6.7 -27.2] months) and OS (20.3 [11.3-38.3] months) compared with patients with KRAS wild-type tumors (DFS, 16.2 [8.9-30.5] months; OS, 38.6 [16.6-63.1] months) and had 5-year OS of 13.0% vs 30.2%. Particularly poor outcomes were identified in patients with KRAS G12D-mutant tumors, who had a median (IQR) OS of 15.3 (9.8-32.7) months. Patients whose tumors lacked CDKN2A expression had worse DFS (median, 11.5 [IQR, 6.2-24.5] months) and OS (19.7 [10.9-37.1] months) compared with patients who had intact CDKN2A (DFS, 14.8 [8.2-30.5] months; OS, 24.6 [14.1-44.6] months). The molecular status of SMAD4 was not associated with DFS or OS, whereas TP53 status was associated only with shorter DFS (HR, 1.33; 95% CI, 1.02-1.75; P = .04). Patients had worse DFS and OS if they had a greater number of altered driver genes. Compared with patients with 0 to 2 altered genes, those with 4 altered genes had worse DFS (HR, 1.79 [95% CI, 1.24-2.59; P = .002]) and OS (HR, 1.38 [95% CI, 0.98-1.94; P = .06]). Five-year OS was 18.4% for patients with 0 to 2 gene alterations, 14.1% for those with 3 alterations, and 8.2% for those with 4 alterations. Conclusions and Relevance: Patient outcomes are associated with alterations of the 4 main driver genes in resected pancreatic adenocarcinoma.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:Publisher
[do] DOI:10.1001/jamaoncol.2017.3420


  8 / 231031 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29097877
[Au] Autor:Manabe S; Mukaisho KI; Yasuoka T; Usui F; Matsuyama T; Hirata I; Boku Y; Takahashi S
[Ad] Dirección:Department of Gastroenterology, Kouseikai Takeda Hospital, Kyoto 600-8558, Japan. s-manabe@takedahp.or.jp.
[Ti] Título:Gastric adenocarcinoma of fundic gland type spreading to heterotopic gastric glands.
[So] Fuente:World J Gastroenterol;23(38):7047-7053, 2017 Oct 14.
[Is] ISSN:2219-2840
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Herein, we present a case of gastric adenocarcinoma of fundic gland type (GA-FG) spreading to heterotopic gastric glands (HGG) in the submucosa. A 58-year-old man with epigastric pain was referred to our hospital and underwent an esophagogastroduodenoscopy. A Borrmann type II gastric cancer at the antrum and a 10 mm submucosal tumor-like lesion in the lesser curvature of the upper third of the stomach were detected. Histological examination of the biopsy specimens obtained from the submucosal tumor-like lesion suggested a GA-FG. Therefore, endoscopic submucosal dissection was performed as excisional biopsy, and histopathological examination of the resected specimen confirmed a GA-FG and HGG proximal to the GA-FG. Although the GA-FG invaded the submucosal layer slightly, the submucosal lesion of the GA-FG had a poor stromal reaction and was located just above the HGG in the submucosa. Therefore, we finally diagnosed the lesion as a GA-FG invading the submucosal layer by spreading to HGG.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:In-Process
[do] DOI:10.3748/wjg.v23.i38.7047


  9 / 231031 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29097801
[Au] Autor:Fan CC; Cheng WC; Huang YC; Sher YP; Liou NJ; Chien YC; Lin PS; Lin PS; Chen CH; Chang WC
[Ad] Dirección:Department of Superintendent Office, Mackay Memorial Hospital, Taipei, Taiwan.
[Ti] Título:EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma.
[So] Fuente:Sci Rep;7(1):14617, 2017 Nov 06.
[Is] ISSN:2045-2322
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:Surgery is the only curative treatment for early-stage non-small cell lung cancer (NSCLC) patients. However, approximately one-third of these patients develop recurrence, which remains the main cause of mortality in the postsurgical treatment of NSCLC. Many molecular markers have been proposed to predict recurrence of early-stage disease, but no marker has demonstrated sufficient reliability for clinical application. In the present study, the novel protein EF-hand domain-containing protein D2 (EFHD2) was identified as expressed in highly metastatic tumor cells. EFHD2 increased the formation of protrusive invadopodia structures and cell migration and invasion abilities and promoted the epithelial-to-mesenchymal transition (EMT) character of lung adenocarcinoma cells. We demonstrated that the mechanism of EFHD2 in enhancing EMT occurs partly through inhibition of caveolin-1 (CAV1) for cancer progression. The expression of EFHD2 was significantly correlated with postsurgical recurrence of patients with stage I lung adenocarcinoma in the Kaplan-Meier-plotter cancer database search and our retrospective cohort study (HR, 6.14; 95% CI, 2.40-15.74; P < 0.001). Multivariate Cox regression analysis revealed that EFHD2 expression was an independent clinical predictor for this disease. We conclude that EFHD2 expression is associated with increased metastasis and EMT and could serve as an independent marker to predict postsurgical recurrence of patients with stage I lung adenocarcinoma.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:In-Data-Review
[do] DOI:10.1038/s41598-017-15186-y


  10 / 231031 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29097253
[Au] Autor:Bucciarelli PR; Tan KS; Chudgar NP; Brandt W; Montecalvo J; Eguchi T; Liu Y; Aly R; Travis WD; Adusumilli PS; Jones DR
[Ad] Dirección:Department of Surgery, Epidemiology and Biostatistics.
[Ti] Título:BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
[So] Fuente:J Thorac Oncol;, 2017 Oct 30.
[Is] ISSN:1556-1380
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:INTRODUCTION: Expression of breast cancer metastasis suppressor 1 (BRMS1) is decreased in non-small cell lung cancer cells and tumors. We hypothesized that intratumoral BRMS1 expression is associated with lung adenocarcinoma (LUAD) histologic subtypes and overall survival (OS) and disease-free survival (DFS) in patients undergoing resection for early-stage LUAD. METHODS: Patients (n=1030) who underwent complete resection for LUAD with tissue available for histologic evaluation were identified. Tissue microarrays were constructed, and immunostaining was performed and scored for intensity of BRMS1 expression. OS and DFS were estimated (Kaplan-Meier method) and compared between groups (log-rank test), stratified by stage. Hazard ratios (HRs) for hazard of death and recurrence were estimated using univariable and multivariable Cox proportional hazards models. OS and DFS nomograms were created, and model performance was examined. RESULTS: Intratumoral BRMS1 expression was high in 632 (61%) and low in 398 (39%) patients. Low BRMS1 expression was associated with higher pathologic T stage (P=0.001), larger tumor size (P≤0.0001), greater lymphatic (P=0.032) and vascular (P=0.001) invasion, LUAD histologic subtypes (P=0.001), and intermediate and high architectural tumor grade (P=0.003). Low BRMS1 expression was an independent predictor of worse OS (HR, 1.35 [95% CI, 1.10-1.65]; P=0.004) and DFS (HR, 1.27 [95% CI, 1.05-1.54]; P=0.012). OS and DFS nomograms showed excellent predictive performance based on discrimination and calibration. CONCLUSIONS: Among patients with surgically resected LUAD, OS and DFS were significantly worse in low intratumoral BRMS1 expression. Our findings suggest BRMS1 is an independent biomarker with prognostic significance in surgically resected LUAD.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171103
[Lr] Fecha última revisión:171103
[St] Status:Publisher



página 1 de 23104 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud